C2N Diagnostics
VerifiedDeveloping innovative diagnostics for Alzheimer's disease and related neurodegenerative conditions.
Launch date
Employees
Market cap
-
Net debt
-
Enterprise valuation
$60—90m (Dealroom.co estimates Mar 2024.)
St. Louis Missouri (HQ)